PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Main active ingredients (astragaloside, flavonoids, and polysaccharides) have a significant therapeutic effect in animal models [PMID:37722514]
Polysaccharides (mAPS) significantly decreased body weight, fasting blood glucose, and HOMA-IR in rats [PMID:40486274]
Extracts alleviate myocardial remodeling caused by hypertension in rats via ESR1 downregulation of the RhoA/ROCK pathway [PMID:37967985]
Polysaccharides (mAPS) alleviate kidney injury by modulating oxidation, inflammation, and gut microbiota in rats [PMID:40003935]
Astragalus polysaccharides (APS) demonstrate anti-NAFLD effects in high-fat diet-fed mice via gut microbiome modulation [PMID:34125646]
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 37019161 (2023) — YuPingFengSan ameliorates LPS-induced acute lung injury and gut barrier dysfunction in mice. · Journal of ethnopharmacology
- 2.PMID: 34125646 (2021) — Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. · Gut microbes
- 3.PMID: 38308918 (2024) — Ononin promotes radiosensitivity in lung cancer by inhibiting HIF-1α/VEGF pathway. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 4.PMID: 36408254 (2022) — Astragalus and its formulas as a therapeutic option for fibrotic diseases: Pharmacology and mechanisms. · Frontiers in pharmacology
- 5.PMID: 39726784 (2024)